-
1.发明授权IVIG modulation of chemokines for treatment of multiple sclerosis, alzheimer's disease, and parkinson's disease 有权用于治疗多发性硬化，阿尔茨海默氏病和帕金森病的趋化因子的IVIG调节公开(公告)号：US07968293B2
公开(公告)日：2011-06-28
申请号：US12189367
申请日：2008-08-11
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
摘要翻译： 本发明提供用于提供治疗与脑炎性疾病相关疾病（包括MS）的预后的方法，例如使用显示为过表达的分子标记物复发性缓解多发性硬化（RRMS），阿尔茨海默氏病和帕金森病 或在静脉注射免疫球蛋白（IVIG）治疗的患者中未表达。 还提供了鉴定可用于治疗或预防MS的化合物的方法，例如复发缓解多发性硬化症（RRMS），阿尔茨海默病和帕金森病。
-
2.发明申请IVIG MODULATION OF CHEMOKINES FOR TREATMENT OF MULTIPLE SCLEROSIS, ALZHEIMER'S DISEASE, AND PARKINSON'S DISEASE 有权用于治疗多发性硬化症，阿尔茨海默病和帕金森病的化疗药物的IVIG调节公开(公告)号：US20090148463A1
公开(公告)日：2009-06-11
申请号：US12189367
申请日：2008-08-11
IPC分类号： A61K39/395 , G01N33/53 , A61P25/00 , A61P37/06 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158
摘要： The present invention provides methods for providing a prognosis of treatment of diseases associated with inflammatory disease of the brain, including MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease using molecular markers that are shown to be overexpressed or underexpressed in patients treated with intravenous immunoglobulins (IVIG). Also provided are methods to identify compounds that are useful for the treatment or prevention of MS, e.g., relapsing-remitting multiple sclerosis (RRMS), Alzheimer's disease, and Parkinson's disease.
摘要翻译： 本发明提供用于提供治疗与脑炎性疾病相关疾病（包括MS）的预后的方法，例如使用显示为过表达的分子标记物复发性缓解多发性硬化（RRMS），阿尔茨海默氏病和帕金森病 或在静脉注射免疫球蛋白（IVIG）治疗的患者中未表达。 还提供了鉴定可用于治疗或预防MS的化合物的方法，例如复发缓解多发性硬化症（RRMS），阿尔茨海默病和帕金森病。
-
3.发明授权公开(公告)号：US08852874B2
公开(公告)日：2014-10-07
申请号：US12392267
申请日：2009-02-25
IPC分类号： G01N33/68 , G01N33/50 , C12Q1/32 , A61K39/395
CPC分类号： G01N33/5014 , G01N33/5008 , G01N33/5058 , G01N33/6896 , G01N2333/4709 , G01N2500/10
摘要： The present invention relates to a cell-based in vitro screening assay for identifying and selecting therapeutic agents that inhibit amyloid β-induced cytotoxicity.
摘要翻译： 本发明涉及用于鉴定和选择抑制淀粉样蛋白和细胞毒性的治疗剂的基于细胞的体外筛选测定。
-
4.发明申请ANTI-AMYLOID BETA ACTIVITY OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN VITRO 有权体内静脉注射免疫球蛋白（IVIG）的抗氨基酸活性公开(公告)号：US20090221017A1
公开(公告)日：2009-09-03
申请号：US12392267
申请日：2009-02-25
CPC分类号： G01N33/5014 , G01N33/5008 , G01N33/5058 , G01N33/6896 , G01N2333/4709 , G01N2500/10
摘要： The present invention relates to a cell-based in vitro screening assay for identifying and selecting therapeutic agents that inhibit amyloid r-induced cytotoxicity.
摘要翻译： 本发明涉及用于鉴定和选择抑制淀粉样蛋白r诱导的细胞毒性的治疗剂的基于细胞的体外筛选测定。
-
5.发明申请Transgenic Non-Human Animals Expressing Human Blood Clotting Factors and Uses Thereof 有权表达人血液凝血因子的转基因非人动物及其用途公开(公告)号：US20120082987A1
公开(公告)日：2012-04-05
申请号：US13071190
申请日：2011-03-24
申请人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Reipert , Gerhard Antoine , Hartmut Ehrlich
发明人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Reipert , Gerhard Antoine , Hartmut Ehrlich
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/15 , A01K2227/105 , A01K2267/02 , A01K2267/03 , C07K14/745 , C07K14/755 , C12N9/64
摘要： The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
摘要翻译： 本发明一般涉及表达人血液凝固因子如因子VIII，因子VII，因子IX和血管性血友病因子的非人转基因动物的开发。 本发明还提供使用所述转基因动物检测针对人血液凝固因子的免疫原性事件的方法。
-
6.发明申请Transgenic Non-Human Animals Expressing Human Blood Clotting Factors and Uses Thereof 审中-公开表达人血液凝血因子的转基因非人动物及其用途公开(公告)号：US20090235369A1
公开(公告)日：2009-09-17
申请号：US12346432
申请日：2008-12-30
申请人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Reipert , Gerhard Antoine , Hartmut Ehrlich
发明人： Maria Sasgary , Maria Schuster , Hans-Peter Schwarz , Birgit Reipert , Gerhard Antoine , Hartmut Ehrlich
IPC分类号： G01N33/53 , A01K67/027 , C12N15/89
CPC分类号： C12N15/8509 , A01K67/0275 , A01K2207/15 , A01K2217/00 , A01K2217/15 , A01K2227/105 , A01K2267/02 , A01K2267/03 , C07K14/745 , C07K14/755 , C12N9/64
摘要： The present invention relates, in general, to development of non-human transgenic animals expressing a human blood clotting factor, such as Factor VIII, Factor VII, Factor IX and von Willebrand factor. The invention further provides methods of detecting immunogenic events against human blood clotting factor using the transgenic animals described.
摘要翻译： 本发明一般涉及表达人血液凝固因子如因子VIII，因子VII，因子IX和血管性血友病因子的非人转基因动物的开发。 本发明还提供使用所述转基因动物检测针对人血液凝固因子的免疫原性事件的方法。
-
公开(公告)号：US08969524B2
公开(公告)日：2015-03-03
申请号：US13283452
申请日：2011-10-27
申请人： Katharina Nora Steinitz , Paula Maria Wilhelmina van Helden , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
发明人： Katharina Nora Steinitz , Paula Maria Wilhelmina van Helden , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
IPC分类号： A61K38/37 , C07K14/745 , G01N33/50
CPC分类号： C07K14/755 , A61K38/37 , C07K2319/00 , C12P21/00 , G01N33/505 , G01N33/56977
摘要： The present invention is related to peptides that can be used to reduce the immune response against FVIII or to induce tolerance to human FVIII in patients with, e.g., hemophilia A. Furthermore, the peptides can be used for immunodiagnostic purposes to detect FVIII-specific CD4+ T cells to monitor patients with hemophilia A during replacement therapy and during immune tolerance induction therapy.
摘要翻译： 本发明涉及可用于降低针对FVIII的免疫应答或诱导对例如血友病A的患者对人FVIII的耐受性的肽。此外，该肽可用于免疫诊断目的以检测FVIII-特异性CD4 + T细胞在替代治疗期间和免疫耐受诱导治疗期间监测血友病A患者。
-
8.发明授权Detection of antibody that binds to water soluble polymer-modified polypeptides 有权检测结合水溶性聚合物修饰多肽的抗体公开(公告)号：US08216793B2
公开(公告)日：2012-07-10
申请号：US12786641
申请日：2010-05-25
申请人： Christian Lubich , Juergen Siekmann , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
发明人： Christian Lubich , Juergen Siekmann , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
IPC分类号： G01N33/566
CPC分类号： G01N33/6854
摘要： The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.
摘要翻译： 本发明提供了检测个体抗体抗体的分析方法。 所述方法包括使来自个体的样品与水溶性聚合物修饰的载体接触并检测抗体与水溶性聚合物修饰的载体上的水溶性聚合物的结合，其中结合指示抗体存在于聚合物修饰的水 多肽。 可以对水溶性聚合物如聚乙二醇，聚唾液酸，葡聚糖，羟烷基淀粉或羟乙基淀粉检测抗体。 当检测到对水溶性聚合物聚乙二醇的抗体时，用非线性聚乙二醇衍生物修饰载体。
-
9.发明申请公开(公告)号：US20110070592A1
公开(公告)日：2011-03-24
申请号：US12786641
申请日：2010-05-25
申请人： Christian Lubich , Juergen Siekmann , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
发明人： Christian Lubich , Juergen Siekmann , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
IPC分类号： G01N33/566
CPC分类号： G01N33/6854
摘要： The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.
摘要翻译： 本发明提供了检测个体抗体抗体的分析方法。 所述方法包括使来自个体的样品与水溶性聚合物修饰的载体接触并检测抗体与水溶性聚合物修饰的载体上的水溶性聚合物的结合，其中结合指示抗体存在于聚合物修饰的水 多肽。 可以对水溶性聚合物如聚乙二醇，聚唾液酸，葡聚糖，羟烷基淀粉或羟乙基淀粉检测抗体。 当检测到对水溶性聚合物聚乙二醇的抗体时，用非线性聚乙二醇衍生物修饰载体。
-
10.发明申请DETECTION OF ANTIBODY THAT BINDS TO WATER SOLUBLE POLYMER-MODIFIED POLYPEPTIDES 审中-公开检测抗水溶性聚合物改性多糖的抗体公开(公告)号：US20120309021A1
公开(公告)日：2012-12-06
申请号：US13489925
申请日：2012-06-06
申请人： Christian Lubich , Juergen Siekmann , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
发明人： Christian Lubich , Juergen Siekmann , Birgit Maria Reipert , Hans-Peter Schwarz , Hartmut Ehrlich
IPC分类号： G01N33/566 , G01N33/573
CPC分类号： G01N33/6854
摘要： The present invention provides analytical methods for detecting anti-polymer antibody in an individual. The methods involve contacting a sample from the individual with a water soluble polymer-modified carrier and detecting binding of antibody to the water soluble polymer on the water soluble polymer-modified carrier wherein binding is indicative of the presence of antibody to the water polymer-modified polypeptide. Antibody may be detected to water soluble polymers such as polyethylene glycol, polysialic acid, dextran, hydroxyalkyl starch, or hydroxyethyl starch. When antibody to the water soluble polymer polyethylene glycol is to be detected, the carrier is modified with a non-linear polyethylene glycol derivative.
摘要翻译： 本发明提供了检测个体抗体抗体的分析方法。 所述方法包括使来自个体的样品与水溶性聚合物修饰的载体接触并检测抗体与水溶性聚合物修饰的载体上的水溶性聚合物的结合，其中结合指示抗体存在于聚合物修饰的水 多肽。 可以对水溶性聚合物如聚乙二醇，聚唾液酸，葡聚糖，羟烷基淀粉或羟乙基淀粉检测抗体。 当检测到对水溶性聚合物聚乙二醇的抗体时，用非线性聚乙二醇衍生物修饰载体。
-
-
-
-
-
-
-
-
-
搜索结果
113 条记录 (耗时 0.026 秒)
